Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Everolimuseluting Stent

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00378612Phase 3CompletedPrimary

ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial

NCT01012869Phase 4CompletedPrimary

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study

Showing all 2 trials

Research Network

Common Treatments

  • Everolimuseluting Stent1
  • Cypher Sirolimus Eluting Coronary Stent1

Active Sponsors

  • Cordis US Corp.1
  • North Texas Veterans Healthcare System1
  • Sunil Rao1

Top Investigators

Activity Timeline